Form 4 for ALXO ALX ONCOLOGY HOLDINGS INC
Accepted 2024-02-16 00:00:00 ET · period of report 2024-02-14 · accession 0001415889-24-004210 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-16 | 2024-02-14 | ALXO | Lettmann Jason | CEO, Dir | A - Grant | $0.00 | +60.0K | 167.2K | +56% | $0 |
| D | 2024-02-16 | 2024-02-14 | ALXO | Lettmann Jason | CEO, Dir | A - Grant | $0.00 | +190.0K | 190.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-14 | A | A | 60,000 | $0.00 | 167,220 | D | — | — | (F1) The reported shares are represented by restricted stock units, or RSUs, which vest in eight equal semiannual installments beginning on August 14, 2024. |
| 2 | Derivative | Employee Stock Option | 2024-02-14 | A | A | 190,000 | $0.00 | 190,000 | D | $15.84 · — to 2034-02-13 | 190,000 Common Stock | (F2) Shares subject to the option vest in 48 equal monthly installments beginning on March 14, 2024. |